source:[1] Alzheimer Diseae Drug Development Shifts as Tau Antibody Research Falters - Patient Care Online (https://www.patientcareonline.com/view/alzhei ...)[2] Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy - BioSpace (https://www.biospace.com/press-releases/avice ...)[3] Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout - Fierce Biotech (https://www.fiercebiotech.com/biotech/kyverna ...)